Fate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
FATE Nasdaq 2834 www.fatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fate Therapeutics, Inc.

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 7:40 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - May 13th, 2026 6:30 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting - May 11th, 2026 6:30 am
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 5:05 pm
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - May 6th, 2026 8:00 am
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 7:30 am
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - May 5th, 2026 6:30 am
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - May 4th, 2026 7:00 am
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 2:05 pm
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting - Apr 30th, 2026 7:00 am
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting - Apr 16th, 2026 7:00 am
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference - Apr 15th, 2026 11:02 pm
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - Apr 9th, 2026 7:00 am
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference - Mar 16th, 2026 2:02 am
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Mar 4th, 2026 2:05 pm
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - Mar 3rd, 2026 2:05 pm
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Feb 26th, 2026 11:30 am
Fate Therapeutics: Q4 Earnings Snapshot - Feb 26th, 2026 7:15 am
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Feb 26th, 2026 7:00 am
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Dec 21st, 2025 7:24 am